Genfit : Les résultats de VS-01 sont attendus pour le S2 2025
>Le lancement d’Iqirvo progresse « comme prévu » - En amont du congrès de l’AASLD qui se tiendra du 15 au 19 novembre, Genfit a réalisé un point sur les avancées en cours de son portefeuille qu’il soit commercial ou clinique.Tout d’abord, les termes employés pour qualifier le lancement d’Iqirvo par Ipsen (partenaire de Genfit) sont encourageants soulignant notamment des développements commerciaux et réglementaires positifs que ce soit aux États-Unis ou en Europe....Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.